235 related articles for article (PubMed ID: 21508308)
1. HIV-1 vaccines and adaptive trial designs.
Corey L; Nabel GJ; Dieffenbach C; Gilbert P; Haynes BF; Johnston M; Kublin J; Lane HC; Pantaleo G; Picker LJ; Fauci AS
Sci Transl Med; 2011 Apr; 3(79):79ps13. PubMed ID: 21508308
[TBL] [Abstract][Full Text] [Related]
2. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
Tomaras GD; Plotkin SA
Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of primate models for AIDS.
Haigwood NL
AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
[TBL] [Abstract][Full Text] [Related]
4. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.
Watkins DI; Burton DR; Kallas EG; Moore JP; Koff WC
Nat Med; 2008 Jun; 14(6):617-21. PubMed ID: 18535579
[TBL] [Abstract][Full Text] [Related]
5. The design and evaluation of HIV-1 vaccines.
Saunders KO; Rudicell RS; Nabel GJ
AIDS; 2012 Jun; 26(10):1293-302. PubMed ID: 22706011
[TBL] [Abstract][Full Text] [Related]
6. New clinical trial designs for HIV vaccine evaluation.
Moodie Z; Janes H; Huang Y
Curr Opin HIV AIDS; 2013 Sep; 8(5):437-42. PubMed ID: 23872613
[TBL] [Abstract][Full Text] [Related]
7. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
Rolland M; Gilbert P
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of AIDS vaccine strategies in nonhuman primates.
Uberla K
Med Microbiol Immunol; 2005 Aug; 194(4):201-6. PubMed ID: 15843997
[TBL] [Abstract][Full Text] [Related]
9. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
10. HIV vaccine development at the turn of the 21st century.
Girard MP; Plotkin SA
Curr Opin HIV AIDS; 2012 Jan; 7(1):4-9. PubMed ID: 22156840
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
Girard MP; Osmanov S; Assossou OM; Kieny MP
Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
[TBL] [Abstract][Full Text] [Related]
12. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
[TBL] [Abstract][Full Text] [Related]
13. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
[TBL] [Abstract][Full Text] [Related]
14. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut LH; Ertl HC
J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
[TBL] [Abstract][Full Text] [Related]
15. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
16. New directions for HIV vaccine development from animal models.
McChesney MB; Miller CJ
Curr Opin HIV AIDS; 2013 Sep; 8(5):376-81. PubMed ID: 23836045
[TBL] [Abstract][Full Text] [Related]
17. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
[TBL] [Abstract][Full Text] [Related]
18. Progress toward an HIV vaccine.
Letvin NL
Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
[TBL] [Abstract][Full Text] [Related]
19. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
20. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
